Edwards Lifesciences (NYSE:EW – Get Free Report) issued an update on its third quarter earnings guidance on Wednesday morning. The company provided EPS guidance of $0.67-0.71 for the period, compared to the consensus EPS estimate of $0.69. The company issued revenue guidance of $1.56-1.64 billion, compared to the consensus revenue estimate of $1.62 billion. Edwards Lifesciences also updated its Q3 2024 guidance to 0.670-0.710 EPS.
Edwards Lifesciences Trading Down 31.3 %
NYSE:EW traded down $27.25 during trading hours on Thursday, hitting $59.70. 45,959,203 shares of the stock were exchanged, compared to its average volume of 3,698,478. The company’s 50 day moving average is $89.12 and its two-hundred day moving average is $87.12. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $96.12. The company has a quick ratio of 2.67, a current ratio of 3.75 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $35.98 billion, a P/E ratio of 26.20, a price-to-earnings-growth ratio of 3.19 and a beta of 1.11.
Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. During the same quarter in the prior year, the business earned $0.66 EPS. The business’s revenue for the quarter was up 6.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Edwards Lifesciences will post 2.77 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on Edwards Lifesciences
Insider Buying and Selling
In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at $4,378,659.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Edwards Lifesciences news, CFO Scott B. Ullem sold 5,625 shares of the firm’s stock in a transaction that occurred on Tuesday, May 21st. The shares were sold at an average price of $90.45, for a total transaction of $508,781.25. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at $2,764,242.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 10th. The stock was sold at an average price of $93.29, for a total transaction of $466,450.00. Following the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $4,378,659.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,099 shares of company stock worth $7,003,553. Company insiders own 1.29% of the company’s stock.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
See Also
- Five stocks we like better than Edwards Lifesciences
- What Are the FAANG Stocks and Are They Good Investments?
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- Stock Market Upgrades: What Are They?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- Options Trading – Understanding Strike Price
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.